Insomnia Therapy
Insomnia Therapy - Related Videos
01:27
Insomnia
0 Views •
2024
Insomnia is a prevalent sleep disorder characterized by difficulty falling asleep, frequent awakenings during the night, and waking up too early without being able to return to sleep. People with insomnia often experience these disruptions at least three nights a week for at least one month. Chronic insomnia, which lasts for at least three months, can lead to increased anxiety, which in turn can worsen sleep difficulties, creating a cycle of sleeplessness and stress. Multiple factors contribute...
01:19
Management of Insomnia
0 Views •
2024
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
04:59
Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
0 Views •
2025
This protocol presents the clinical efficacy of heat-sensitive moxibustion in treating chronic obstructive pulmonary disease (COPD) combined with insomnia and outlines the procedure for heat-sensitive moxibustion.
04:34
Meta-Analysis of the Effectiveness and Safety of Shugan Jieyu Capsules for the Treatment of Insomnia
0 Views •
Cited by 3 •
2023
The presented protocol describes an investigation strategy and systematic review to evaluate the clinical effectiveness and safety of Shugan Jieyu capsules for treating insomnia.
01:26
Group Therapy
0 Views •
2025
Group therapy is a sociocultural approach to psychological treatment, where individuals with shared psychological challenges come together under the guidance of a mental health professional. This therapeutic modality offers unique opportunities for individuals to connect, share, and grow within the context of a supportive group. By fostering mutual understanding and collaboration, group therapy can address a range of psychological concerns effectively, often complementing or surpassing the...
FAQs
Medication choice reflects the signaling system being modified. GABA-A receptor-targeting drugs, melatonin-receptor-targeting drugs, and agents acting on orexin signaling represent distinct pharmacological approaches. Comparing these targets helps explain why therapies may differ in their effects on sleep initiation or maintenance, and it gives pharmacologists a framework for matching treatment characteristics to an individual’s needs.
These components address different contributors to persistent sleep difficulty. Stimulus control strengthens the relationship between appropriate sleep cues and sleep, sleep scheduling organizes the timing of sleep, and cognitive restructuring reduces unhelpful cognitive arousal. Together, they target behavioral and cognitive patterns that can interfere with initiating or maintaining sleep.
Onset and duration of action help distinguish treatments according to when effects begin and how long they persist. Adverse effects, tolerance, and interactions add safety considerations that cannot be separated from efficacy. In pharmacology, evaluating these properties together supports individualized prescribing rather than judging a therapy only by whether it improves sleep.
Treatment response can be considered across several linked outcomes: shorter time to fall asleep, fewer nighttime awakenings, and better daytime performance. Looking at both nighttime sleep and daytime functioning matters because improvement is not limited to sleep initiation alone. These measures help distinguish a change in one symptom from broader functional benefit.
A combined approach may be considered when treatment planning calls for both behavioral and pharmacological components. The rationale is to address sleep-related behaviors and cognitive arousal through CBT-I while also using a medication mechanism involving GABA-A receptors, melatonin receptors, or orexin signaling. The choice should reflect onset, duration, adverse effects, tolerance, and interactions.
Pharmacology provides a structured way to compare therapies beyond their intended sleep benefit. Clinicians and researchers can examine receptor or signaling targets alongside onset and duration of action, adverse effects, tolerance, and interactions. This integrated comparison supports safer, more individualized decisions and helps relate a treatment’s mechanism to sleep initiation, sleep maintenance, and daytime outcomes.